logo
HIV: Supercharged Vaccine Could Protect Well With Just One Dose

HIV: Supercharged Vaccine Could Protect Well With Just One Dose

Newsweek6 hours ago

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A supercharged HIV vaccine could offer strong protection with just one injection, a study in mice has indicated.
Developed by researchers from the Massachusetts Institute of Technology (MIT) and the Scripps Research Center, the vaccine includes two "adjuvants"—materials that help stimulate the immune system response.
In the experiments, the dual-adjuvant vaccine was found to produce a wider diversity of antibodies to protect against an HIV protein than with either single adjuvant or none at all.
This was because the vaccine accumulated in the mice's lymph nodes and remained there for a month—giving their immune systems more time to build up antibodies against HIV.
"What's potentially powerful about this approach is that you can achieve long-term exposures based on a combination of adjuvants that are already reasonably well-understood, so it doesn't require a different technology," said paper author and MIT chemical engineer professor J. Christopher Love in a statement.
And, the researchers said, the same approach could be used to create one-shot-only vaccines against other diseases, including COVID-19 and influenza.
A man receives a vaccination.
A man receives a vaccination.
Rani Nurlaela Desandi/iStock / Getty Images Plus
Most vaccines administered today are accompanied by adjuvants to help make them more effective.
One often used with protein-based vaccines—such as given against hepatitis A and B—is "alum," short for "aluminum hydroxide." Alum activates the body's innate immune response, helping it to form a stronger memory of the vaccine antigen in case of a real infection.
The new HIV vaccine combines alum with a nanoparticle known as SMNP, which itself combines the FDA-approved, naturally derived adjacent saponin with an inflammation-promoting molecule.
In their study, the researchers found that the SMNP–alum combination helped the HIV protein in their vaccine both penetrate the protective layer of cells surrounding the lymph nodes without being broken down, as well as stay intact in the nodes for up to 28 days.
The lymph nodes are where protective "B cells" are exposed to antigens—the substances that the body uses to recognize a given infection—and learn to produce the antibodies to fight back.
Vaccine antigens (pink) concentrate in B cell follicles (cyan)
Vaccine antigens (pink) concentrate in B cell follicles (cyan)
MIT
"As a result, the B cells that are cycling in the lymph nodes are constantly being exposed to the antigen over that [up to 28 day] time period—and they get the chance to refine their solution to the antigen," Love explained.
He added: "When you think about the immune system sampling all of the possible solutions, the more chances we give it to identify an effective solution, the better."
When the researchers analyzed the RNA of the B cells from the vaccinated mice, they found that those who had received both adjuvants had produced a more diverse array of B Cells and antibodies than the other rodents.
In fact, those who received the dual-adjuvant vaccine produced more than twice as many unique B cells than those mice who received a single-adjuvant vaccine.
This, the team explained, increases the odds that the mice's immune systems will be able to produce antibodies against a variety of strains of HIV in the case of a future injection.
And the benefits of the dual-adjuvant tactic is not just limited to fighting HIV.
"This approach is compatible with many protein-based vaccines, so it offers the opportunity to engineer new formulations for these types of vaccines across a wide range of different diseases, such as influenza, SARS-CoV-2, or other pandemic outbreaks," said Love.
Do you have a tip on a health story that Newsweek should be covering? Do you have a question about HIV? Let us know via health@newsweek.com.
Reference
Rodrigues, K. A., Zhang, Y. J., Lam, J., Aung, A., Morgan, D. M., Romanov, A., Maiorino, L., Yousefpour, P., Gibson, G., Ozorowski, G., Gregory, J. R., Amlashi, P., Van, R., Buckley, M., Ward, A. B., Schief, W. R., Love, J. C., & Irvine, D. J. (2025). Vaccines combining slow release and follicle targeting of antigens increase germinal center B cell diversity and clonal expansion. Science Translational Medicine, 17(803). https://doi.org/10.1126/scitranslmed.adw7499

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

What to know about COVID variant NB.1.8.1 causing 'razor blade throat'
What to know about COVID variant NB.1.8.1 causing 'razor blade throat'

Yahoo

time8 minutes ago

  • Yahoo

What to know about COVID variant NB.1.8.1 causing 'razor blade throat'

A newer COVID-19 variant may be causing a severe sore throat in some people who contract the infection. The variant, known as NB.1.8.1, has been nicknamed by some as "razor blade throat" due to the painful symptom. MORE: Why are more than 300 people in the US still dying from COVID every week? Data from the open global genome sequencing database GISAID shows the new variant has been detected in several states, including New York, Illinois, Texas and California. Public health experts told ABC News there is no cause for serious concern yet because the virus does not appear to be more severe than previous variants and there are steps that can be taken to protect yourself. NB.1.8.1 derives from the recombinant variant XVD.1.5.1, which is a descendant of the omicron variant. The first sample of NB.1.8.1 was collected on Jan. 22, according to the World Health Organization (WHO). It was first detected in China and other parts of Asia before spreading to Europe. It was designated as a "variant under monitoring" by the WHO, meaning it may require prioritized attention and monitoring but is not as serious as a "variant of interest" or a "variant of concern." As of the week ending June 7, NB.1.8.1 is the second most dominant variant in the U.S., accounting for an estimated 37% of cases, according to the Centers for Disease Control and Prevention (CDC). The virus appears to be more transmissible because there appear to be changes to the spike protein, which is what the virus uses to attach to and infect cells, said Dr. Peter Chin-Hong, a professor of medicine and infectious disease specialist at the University of California, San Francisco. It also seems to attach more easily to ACE2 receptors, which are proteins found on the surface of cells and how the virus that causes COVID enters cells, he told ABC News. NB.1.8.1 doesn't yet appear to be causing increases in cases or in hospitalizations with rates remaining "stable" so far, according to Chin-Hong. The variant has also been called "Nimbus," which appears to have been coined on X by T. Ryan Gregory, a Canadian professor of evolutionary biology. "Nimbus is a catchy, quick name, and it also includes an 'N' and a 'B' from the lineage, which is NB.1.8.1. So it's easier for people to be able to say these monikers for COVID, rather than remember the actual lineage," said Dr. Alok Potel, a pediatrician at Stanford Children's Health and an ABC News contributor. "But I think it's important also because it keeps people paying attention to new COVID variants that can be different in terms of infectivity and in terms of spread," he added. MORE: What we still don't know about COVID 5 years after the WHO declared a pandemic Experts said they are not sure if the painful sore throat is just a symptom that people are talking about or a distinctive symptom of this variant. It's also unclear if the "razor blade throat" is more common in those who are more up to date on vaccination compared to those who are not up to date. "I think it's certainly amongst the spectrum of symptoms that you can get, and we know that sore throat is reported by about 70% of patients now with COVID, so it's not unusual, and like with everything in medicine, there's always a spectrum," Chin-Hong said. There is currently no evidence that NB.1.8.1. causes more severe disease or is more likely to cause hospitalization, according to Dr. William Schaffner, a professor of preventive medicine at Vanderbilt University Medical Center in Nashville, MORE: 5 years ago, the WHO declared COVID a pandemic. Here's a look at the disease by the numbers "But of course, there are people in high-risk groups that are still at risk of being hospitalized should they become infected," he told ABC News. There are no other symptoms outlined that are specific to NB.1.8.1 by the CDC. Symptoms listed by the health agency still include sore throat, cough, fever, chills, shortness of breath, difficulty breathing, congestion, runny nose, loss of taste or smell, fatigue, muscle aches, body aches, headache, nausea, vomiting or diarrhea. The experts recommend that high-risk Americans receive a vaccine twice a year as recommended by the CDC. The CDC also currently recommends most adults aged 18 and older receive an updated 2024-2025 vaccine and that parents of children between ages 6 months to 17 years discuss the benefits of vaccination with a health care provider. COVID-19 also tends to spike in the late summer and early fall, so people should consider opening windows to increase ventilation, wearing a mask in certain situations and avoiding crowded areas, Schaffner said. "Time to stream a movie, as I like to say, rather than going to the movies," he added. Patel said it's important to practice good hygiene such as proper hand-washing and covering your mouth when coughing or sneezing. He also recommended that people test if they are symptomatic and said over-the-counter rapid at-home tests work. "Getting infected with COVID and other infectious diseases is not necessarily life or death, but it can still be very debilitating." Patel said. "It can cause people to miss work, to spread the virus, to get people who are higher risk sick and there's still an untold amount of people who have long COVID." He added, "So, we don't want to look at COVID as just another common cold, because there's still so much we're learning about it, and there's still so many possibilities with this virus continuing to mutate, if we let it."

What to know about COVID variant NB.1.8.1 causing 'razor blade throat'

time19 minutes ago

What to know about COVID variant NB.1.8.1 causing 'razor blade throat'

A newer COVID-19 variant may be causing a severe sore throat in some people who contract the infection. The variant, known as NB.1.8.1, has been nicknamed by some as "razor blade throat" due to the painful symptom. Data from the open global genome sequencing database GISAID shows the new variant has been detected in several states, including New York, Illinois, Texas and California. Public health experts told ABC News there is no cause for serious concern yet because the virus does not appear to be more severe than previous variants and there are steps that can be taken to protect yourself. What is NB 1.8.1? NB.1.8.1 derives from the recombinant variant XVD.1.5.1, which is a descendant of the omicron variant. The first sample of NB.1.8.1 was collected on Jan. 22, according to the World Health Organization (WHO). It was first detected in China and other parts of Asia before spreading to Europe. It was designated as a "variant under monitoring" by the WHO, meaning it may require prioritized attention and monitoring but is not as serious as a "variant of interest" or a "variant of concern." As of the week ending June 7, NB.1.8.1 is the second most dominant variant in the U.S., accounting for an estimated 37% of cases, according to the Centers for Disease Control and Prevention (CDC). The virus appears to be more transmissible because there appear to be changes to the spike protein, which is what the virus uses to attach to and infect cells, said Dr. Peter Chin-Hong, a professor of medicine and infectious disease specialist at the University of California, San Francisco. It also seems to attach more easily to ACE2 receptors, which are proteins found on the surface of cells and how the virus that causes COVID enters cells, he told ABC News. NB.1.8.1 doesn't yet appear to be causing increases in cases or in hospitalizations with rates remaining "stable" so far, according to Chin-Hong. The variant has also been called "Nimbus," which appears to have been coined on X by T. Ryan Gregory, a Canadian professor of evolutionary biology. "Nimbus is a catchy, quick name, and it also includes an 'N' and a 'B' from the lineage, which is NB.1.8.1. So it's easier for people to be able to say these monikers for COVID, rather than remember the actual lineage," said Dr. Alok Potel, a pediatrician at Stanford Children's Health and an ABC News contributor. "But I think it's important also because it keeps people paying attention to new COVID variants that can be different in terms of infectivity and in terms of spread," he added. What are the symptoms? Experts said they are not sure if the painful sore throat is just a symptom that people are talking about or a distinctive symptom of this variant. It's also unclear if the "razor blade throat" is more common in those who are more up to date on vaccination compared to those who are not up to date. "I think it's certainly amongst the spectrum of symptoms that you can get, and we know that sore throat is reported by about 70% of patients now with COVID, so it's not unusual, and like with everything in medicine, there's always a spectrum," Chin-Hong said. There is currently no evidence that NB.1.8.1. causes more severe disease or is more likely to cause hospitalization, according to Dr. William Schaffner, a professor of preventive medicine at Vanderbilt University Medical Center in Nashville, "But of course, there are people in high-risk groups that are still at risk of being hospitalized should they become infected," he told ABC News. There are no other symptoms outlined that are specific to NB.1.8.1 by the CDC. Symptoms listed by the health agency still include sore throat, cough, fever, chills, shortness of breath, difficulty breathing, congestion, runny nose, loss of taste or smell, fatigue, muscle aches, body aches, headache, nausea, vomiting or diarrhea. How to protect yourself The experts recommend that high-risk Americans receive a vaccine twice a year as recommended by the CDC. The CDC also currently recommends most adults aged 18 and older receive an updated 2024-2025 vaccine and that parents of children between ages 6 months to 17 years discuss the benefits of vaccination with a health care provider. COVID-19 also tends to spike in the late summer and early fall, so people should consider opening windows to increase ventilation, wearing a mask in certain situations and avoiding crowded areas, Schaffner said. "Time to stream a movie, as I like to say, rather than going to the movies," he added. Patel said it's important to practice good hygiene such as proper hand-washing and covering your mouth when coughing or sneezing. He also recommended that people test if they are symptomatic and said over-the-counter rapid at-home tests work. "Getting infected with COVID and other infectious diseases is not necessarily life or death, but it can still be very debilitating." Patel said. "It can cause people to miss work, to spread the virus, to get people who are higher risk sick and there's still an untold amount of people who have long COVID." He added, "So, we don't want to look at COVID as just another common cold, because there's still so much we're learning about it, and there's still so many possibilities with this virus continuing to mutate, if we let it."

FDA approves twice-a-year shot to prevent HIV
FDA approves twice-a-year shot to prevent HIV

CNN

time33 minutes ago

  • CNN

FDA approves twice-a-year shot to prevent HIV

FDA approves twice-a-year shot to prevent HIV A drug already used to treat HIV has now been given FDA approval to prevent new infections, and the drugmaker says it is remarkably effective. 01:20 - Source: CNN Vertical Top News 14 videos FDA approves twice-a-year shot to prevent HIV A drug already used to treat HIV has now been given FDA approval to prevent new infections, and the drugmaker says it is remarkably effective. 01:20 - Source: CNN Iranian missile strikes major Israeli medical center CNN's International Diplomatic Editor, Nic Robertson, reports from Beer Sheva, Israel, where a hospital was struck during an Iranian attack. Iran said it was targeting an Israeli intelligence and command center 'near a hospital.' There have been no reported deaths from the strike. 01:04 - Source: CNN Israel's defense minister: Khamenei cannot 'continue to exist' Israel's Defense Minister Israel Katz said Iran's Supreme Leader Ayatollah Ali Khamenei cannot be allowed to 'continue to exist,' after an Israeli hospital was struck by an Iranian missile on Thursday. 00:13 - Source: CNN SpaceX Starship rocket explodes An explosion occurred late Wednesday night at SpaceX's Starbase facility in South Texas. A Starship rocket preparing for its tenth flight test experienced a 'major anomaly,' SpaceX says. There were no injuries and all employees are accounted for, according to SpaceX. The cause of the explosion and the extent of any damage are unclear. CNN has reached out to local police and fire departments for more information. 00:35 - Source: CNN Sole survivor of Air India crash mourns brother Vishwash Kumar Ramesh is the only survivor among 242 on board an Air India flight that crashed in Ahmedabad on June 12. On Wednesday Ramesh attended the funeral for his brother, who died in the tragedy. 00:30 - Source: CNN Hear former President Obama's warning about direction of the US Former President Barack Obama warned that the United States is 'dangerously close' to becoming 'consistent with autocracies' during a civic group event in Connecticut. 00:56 - Source: CNN Anne Burrell dead at 55 Anne Burrell, a chef and television personality whose joyful demeanor made her a beloved fixture on the Food Network, has died, according to the network. She was 55. 00:38 - Source: CNN NYC mayoral candidate arrested at immigration court New York City Comptroller and mayoral candidate Brad Lander was released from federal custody Tuesday afternoon, hours after he was arrested by officers at an immigration court in Manhattan when he tried to escort a migrant whom officers were attempting to arrest. 01:48 - Source: CNN Trump's new phone looks a lot like one from China The Trump Organization says its upcoming T1 smartphone will be 'proudly designed and built in the United States.' But experts tell CNN they're skeptical that goal can be achieved-- and say the T1's specifications are strikingly similar to a Chinese-made phone already on the market. 01:07 - Source: CNN This is how the US could get involved in the Israel-Iran conflict CNN's Nick Paton Walsh reports on how the US could get involved in the conflict between Israel and Iran while the countries continue trading strikes for a sixth day, with civilians in flashpoint areas facing waves of attacks. 02:14 - Source: CNN Trump's sons announce mobile phone company Trump Mobile, a wireless service created by the Trump Organization, aims to rival US carrier companies like AT&T, Verizon and T-Mobile. The Trump Organization, run by President Donald Trump's eldest sons Eric and Donald Jr., announced the business and launched a new gold smartphone for pre-order. 01:09 - Source: CNN What Iranian residents are texting to CNN as strikes hit As Israeli strikes zeroed in on Iran's capital city of Tehran, CNN's Clarissa Ward reports from Tel Aviv some of the messages she's received from residents in Iran offering a glimpse into the daily anxieties of living in a country faced with an ever-escalating conflict in the sky. 01:33 - Source: CNN Minnesota suspect went to 4 state lawmaker homes night of shootings The suspect in the killing of a Minnesota lawmaker and her husband in addition to the shooting of another lawmaker and his wife also visited two more politicians' homes, according to authorities. 02:08 - Source: CNN Trump slams G7 for kicking out Russia President Donald Trump kicked off his visit to the G7 summit in Canada by criticizing nations for kicking out Russia eleven years ago. 00:36 - Source: CNN

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store